GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose (GIP-GLP-gas)

Uppsala University

Status and phase: Completed; Phase 1

Conditions: Gastroenterology; Physiology; Endocrinology

Treatments: Other: Glucose-insulinotropic peptide, Glucagon-like peptide-1

Study type: Interventional

Funder types: Other

Identifiers

NCT01079624

K2010-55X -07916-24-3 (Other Grant/Funding Number)

GIP/GLP-gastric empt-APP-hor

Details and patient eligibility

About

Academic phase 1 study which investigates the effects of the two incretin hormones glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite, insulin release and glucose disposal in the body. The hypothesis is that incretin hormones not only stimulate insulin release but also inhibits gastric emptying. This effect can be utilized for further drug development.

Full description

Effects of GIP and GLP-1 on gastric emptying, appetite control and insulin release in relation to glucose levels in the bloodstream. Infusions of GIP and GLP-1 are given under simultaneous gastric emptying study and appetite questionnaires and blood sampling for analysis of insulin, glucose, and other gut hormones such as glucagon, ghrelin, and PYY, as well as those administered, GIP and GLP-1.

Enrollment: 15 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Men and women
• 18-50 years old;
• otherwise healthy and HIV and HCB, HCV negative

Exclusion criteria

• Age >50,
• all types of diseases and drug users.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

15 participants in 2 patient groups, including a placebo group

GIP two doses and GLP-1 one dose

Experimental group

Description:

Intervention with infusion of GIP or GLP-1 intravenously

Treatment:

Other: Glucose-insulinotropic peptide, Glucagon-like peptide-1

Saline infusion

Placebo Comparator group

Description:

Control

Treatment:

Other: Glucose-insulinotropic peptide, Glucagon-like peptide-1